Supernus Pharmaceuticals Inc (SUPN) Shares Bought by Comerica Bank

Comerica Bank increased its position in shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 5.4% during the first quarter, Holdings Channel reports. The institutional investor owned 55,659 shares of the specialty pharmaceutical company’s stock after buying an additional 2,828 shares during the period. Comerica Bank’s holdings in Supernus Pharmaceuticals were worth $1,848,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the stock. HighTower Advisors LLC bought a new stake in Supernus Pharmaceuticals during the third quarter worth approximately $464,000. Sheets Smith Wealth Management acquired a new stake in shares of Supernus Pharmaceuticals during the third quarter valued at about $941,000. State Street Corp increased its stake in shares of Supernus Pharmaceuticals by 3.5% in the fourth quarter. State Street Corp now owns 1,303,228 shares of the specialty pharmaceutical company’s stock valued at $32,910,000 after buying an additional 44,133 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Supernus Pharmaceuticals by 4.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,107,007 shares of the specialty pharmaceutical company’s stock valued at $27,952,000 after buying an additional 51,511 shares during the period. Finally, Trexquant Investment LP acquired a new stake in shares of Supernus Pharmaceuticals during the fourth quarter valued at about $556,000. Institutional investors and hedge funds own 94.94% of the company’s stock.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) opened at 38.85 on Friday. Supernus Pharmaceuticals Inc has a one year low of $17.25 and a one year high of $41.35. The firm has a 50 day moving average price of $34.70 and a 200 day moving average price of $28.58. The company has a market capitalization of $1.95 billion, a P/E ratio of 20.90 and a beta of 1.89.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $0.19 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.22 by $0.03. Supernus Pharmaceuticals had a return on equity of 35.33% and a net margin of 43.38%. The business had revenue of $57.58 million during the quarter, compared to the consensus estimate of $57.91 million. On average, equities research analysts predict that Supernus Pharmaceuticals Inc will post $1.08 EPS for the current fiscal year.

WARNING: This report was originally reported by Mideast Time and is the property of of Mideast Time. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.mideasttime.com/supernus-pharmaceuticals-inc-supn-shares-bought-by-comerica-bank/1770317.html.

Several equities research analysts have issued reports on SUPN shares. Cantor Fitzgerald restated a “buy” rating and issued a $31.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, March 1st. Jefferies Group LLC restated a “buy” rating and issued a $33.00 price target on shares of Supernus Pharmaceuticals in a report on Thursday, March 2nd. Zacks Investment Research upgraded Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Saturday, March 4th. Stifel Nicolaus increased their price target on Supernus Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, April 3rd. Finally, Cowen and Company increased their price target on Supernus Pharmaceuticals from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Thursday, May 11th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $33.43.

In other news, VP Padmanabh P. Bhatt sold 11,806 shares of Supernus Pharmaceuticals stock in a transaction dated Monday, April 24th. The stock was sold at an average price of $32.59, for a total value of $384,757.54. Following the completion of the transaction, the vice president now directly owns 45,500 shares of the company’s stock, valued at approximately $1,482,845. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 2,500 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $35.90, for a total value of $89,750.00. Following the completion of the transaction, the vice president now directly owns 37,500 shares of the company’s stock, valued at $1,346,250. The disclosure for this sale can be found here. Over the last three months, insiders sold 83,806 shares of company stock valued at $2,813,038. Corporate insiders own 6.10% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals Inc (NASDAQ:SUPN).

Receive News & Ratings for Supernus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.